Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Vertex Pharmaceuticals Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The current ratio, a measure of a company’s ability to pay short-term obligations with its short-term assets, exhibits considerable fluctuation over the analyzed period from 2005 to 2025. Initial values indicate a strong liquidity position, followed by periods of decline and subsequent recovery.

Initial Period (2005-2007)
From 2005 to 2007, the current ratio decreased from 3.84 to 2.49. While remaining above 2.0, this represents a notable decline, suggesting a potential shift in working capital management or a faster growth rate of current liabilities relative to current assets.
Volatility and Recovery (2008-2011)
The years 2008 through 2011 demonstrate volatility. A peak of 4.01 is observed in 2008, followed by increases to 4.59 in 2009, then a decline to 2.23 in 2010, and a recovery to 3.39 in 2011. This period suggests responsiveness to changing economic conditions or strategic adjustments in asset and liability management.
Moderate Stability (2012-2015)
Between 2012 and 2015, the current ratio remained relatively stable, fluctuating between 3.67 and 4.20, before decreasing to 2.78 in 2015. This suggests a period of consistent, though not exceptional, short-term liquidity.
Recent Trends (2016-2025)
From 2016 onwards, the current ratio experienced further fluctuations. It decreased to 2.31 in 2016, then increased to a peak of 4.83 in 2022. A subsequent decline to 2.69 in 2023 and a slight recovery to 2.90 in 2025 is observed. The recent trend indicates increased variability, potentially linked to significant changes in the company’s operational scale and financial strategy. The substantial increase in current assets between 2020 and 2022 appears to be a primary driver of the ratio’s peak during that period.

Overall, the current ratio demonstrates a pattern of cyclical changes rather than a consistent upward or downward trend. The company has generally maintained a current ratio above 1.0 throughout the period, indicating an ability to cover its current liabilities with current assets. However, the fluctuations suggest that liquidity management is dynamic and responsive to internal and external factors.


Comparison to Competitors

Vertex Pharmaceuticals Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Vertex Pharmaceuticals Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)